Crystalline form of dolutegravir sodium salt and preparation method therefor

The present invention relates to a new crystalline form of a Dolutegravir sodium salt. Compared with a known crystalline form of the Dolutegravir sodium salt, the new crystalline form according to the present invention has one or more beneficial properties, such as desirable stability in water, high solubility, low hygroscopicity, desirable storage stability, and excellent particle appearance. The present invention further relates to a preparation method of the Dolutegravir sodium salt in the new crystalline form, a pharmaceutical composition thereof, and uses thereof in preparing a medicine for treating and/or preventing HIV-1 infection.